Skip to Content
menu

Change Life Stories

Shanna, Oren and Damian Living with Hereditary Angioedema Type 1

There’s so much uncertainty with rare disease — the best treatment is your own confidence in making the decisions that are right for you.

Read Shanna's story

News Updates

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Read more
View all news updates

Aiming to make the impossible, possible

Our
Mission

Transforming lives of people with severe diseases by developing potentially curative genome editing treatments.

Learn more

Programs
and Pipeline

Each one of us together for patients

Learn more

Full-Spectrum Approach

Opening a new era in medicine

Learn more

Join Us

See how you can change life stories with genome editing.

Learn more